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Abstract. The pharmaceutical industry is knowledge and research-intensive. Due to technological,
socio-political and organisational changes there has been a continuous evolution in the knowledge
base utilized to achieve and maintain competitive advantages in this global industry. There is a gap
in analysing the linkages and effects of those changes on knowledge creation processes associated
with pharmaceutical R&D activities. Our paper looks to fill this gap. We built on an idiosyncratic
research approach – the systematic literature review – and looked to unearth current trends affecting
knowledge creation in international/global pharmaceutical R&D. We reviewed scientific papers published
between 1980 and 2005. Key findings include promising trends in pharmaceutical innovation and
human resource management, and their potential implications on current R&D practices within the
pharmaceutical industry, from managerial and policy-making perspectives.
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1. Introduction
The pharmaceutical industry is research-intensive, and its competitiveness depends on continuous
inventions and innovations. The ultimate embodiment of knowledge creation in the pharmaceutical
industry is the successful commercialization of new drugs, and represents the key competitive factor
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Note: In this paper knowledge is used in its simplest Aristotelian definition as “justified true belief” (Nonaka &
Takeuchi, 1995). Our focus on knowledge creation stems from the knowledge-based view of the firm, where knowledge becomes
the primary resource/asset that confers a sustainable competitive advantage to the firm, promoting knowledge management to the
most important organisational process within the firm (Blackler, 1995; Nonaka et al., 2001).
(e.g. Lipitor, the number one drug in 2005, sold 12,9 thousand million dollars, i.e. 2,3% of world-
wide market sales) and the main means to recover high investments in R&D (in average more than
20% of total sales) and to cope with increasingly lower success rates (Atun, Gurol-Urganci, & Sheridan,
2007; Atun & Sheridan, 2007; Datamonitor, 2004; DiMasi, Grabowski & Vernon, 2004; IMS, 2006).
It is a global industry, highly concentrated in terms of markets (about 90% of total sales in 2005 were
in the Triad countries, i.e. US, Europe and Japan), and key players (top 10 firms had in 2005 more
than 50% of worldwide sales), and is highly dependent on IP rights, specifically on patent protection
(Arlington, Hughes, & Palo, 2002; Bierly & Chakrabarti, 1996; Class, 2002; Datamonitor, 2004; DiMasi
et al., 2004; Gassmann & Reepmeyer, 2005; Hayes & Walsham, 2003; Howells, 2002; IMS, 2006; Rousch,
2001; Salazar, Hackney, & Howells, 2002; Studt, 2003).
Recently, various factors have affected the operation and efficiency of pharmaceutical R&D
processes, e.g. global markets, technology advances, the advent of biotechnology players, focus shifts
on chronic diseases, stronger regulatory concerns regarding safety, price squeezes due to lower health
budgets (particularly in Europe) (Attridge, 2007; Atun & Sheridan, 2007; Class, 2002; Gassmann &
Reepmeyer, 2005; Thomas, 2004). The pharmaceutical companies have struggled to reduce the uncertainty
associated to those factors, however few effects are visible, pace is slow, and little is seen in terms
of efficiency increase in drug development. 
A direct result of these new developments has been the rise of a Research Industry – new
contract research organizations (CROs), some rivalling in size and influence the major pharmaceutical
players, including most biotechnology firms. Arguably these new networks and the consequent
research outsourcing have started to relegate the traditional pharmaceutical innovators to the role
of global knowledge brokers and have put pressure on traditional knowledge creation processes in
pharmaceutical R&D (Galambos & Sturchio, 1998; Gassmann & Reepmeyer, 2005; Hargadon, 1998;
Martin, 2003; Mittra, 2007; Salman & Saives, 2005). The academic community has focused insuffi-
ciently on these matters, so the whole picture is rather “fuzzy”. 
Our research has struggled to reduce the fuzziness and analysed by means of a systematic literature
review (Tranfield, Denyer, & Smart, 2003) a large number of scientific papers published between 1980
and 2005, which focused on international/global knowledge creation processes in pharmaceutical industry.
We further present the methodology and results of this research according to the following structure.
First, we discuss the systematic review methodology and share the protocol used to perform the review.
Then we present and analyze data collected and we share the main results. Finally, we discuss the
findings and point out relevant trends that may affect the knowledge creation processes in pharma-
ceutical context, including potential managerial and policy implications.
2. The Systematic Review Methodology: Brief Overview
The purpose of a systematic review is to provide a thorough appreciation of existing research in
a specific field in order to promote evidence-based policy and practice. A systematic literature
review starts with a research question/issue which guides the examination of the relevant literature
(Macpherson & Holt, 2005a; Thorpe, Holt, Macpherson, & Pittaway, 2005; Tranfield et al., 2003).
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The history of the evidence-based systematic review was outlined by Tranfield et al. (2003),
and incorporates lessons and methodologies considered relevant from the medical profession (e.g. Higgins
& Green, Eds., 2005) to inform a protocol for systematic reviews in the business and management
fields. The systematic literature review concept introduces a vigorous methodology that can be
replicable, scientifically-minded and transparent. It aims to minimize bias via exhaustive literature
searches of published material, while it provides an audit trail for the reader regarding the reviewers’
decision processes, procedures and conclusions (Thorpe et al., 2005; Tranfield et al., 2003).
Our review drew from the general stages and protocols outlined by the study of Tranfield and
colleagues (2003), complemented by insights provided by Creswell (2003). We considered three phases:
- Definition of the review scope and protocol;
- Data collection and analysis;
- Discussion of findings and implications on field reviewed.
3. Review Scope and Protocol
Scope
In defining the broader scope we went through an iterative process that determined the key
parameters as follows. 
The primary objective of the systematic review is to perform an exploratory study that increases
the understanding of trends affecting knowledge creation processes in global pharmaceutical R&D. 
The issue addressed is the impact of the new socio-political paradigm on the pharmaceutical
industry, with a primary focus on knowledge creation processes. Since our outcome is connected
to the wider pharmaceutical context, it will lead to new understandings and useful prescriptive
suggestions regarding knowledge creation, management and policy making in pharmaceutical context
and thus will inform future research in the global pharmaceutical R&D context or in other industries
with similar characteristics.
Protocol
The protocol we have developed consists of a number of concrete conceptual steps. The first is
to identify the relevant data for our review. Thus relevant papers for this systematic review would: 
1. develop theoretical models of global pharmaceutical R&D and/or empirical papers that
used qualitative, quantitative and mixed-methods. Reasoning: our review should not be
biased either by method or by type (empirical/theoretical). Such a decision assumes that
theory-based modelling as well as field work present credible views and understandings
of the processes of knowledge creation in the industry.
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2. cross-refer to organizations and institutions at different stages of development. Reasoning:
we wished to avoid limiting ourselves to certain types of pharmaceutical companies, or companies
that are under specific pressures. 
3. focus on how knowledge and innovation networks for R&D are formed between pharmaceutical
companies or/and with biotech companies and other partners. Reasoning: we wanted in
particular to examine the results of environmental pressures (e.g. globalisation; new technologies;
new political pressures) to the structures and organisational arrangements within the pharma-
ceutical industry. One of the major responses to these changes has been the formation of
extensive collaboration networks and the formation of alliances with the biotech firms. This
has led to knowledge creation, especially in the form of bio-science drugs.
4. be published in peer-reviewed journals. Reasoning: it is assumed here that peer-reviewed
journals would ensure a higher quality and credibility of the source papers and thus would
inform credibly the systematic literature review. 
Thus in general our criteria for paper inclusion aim to separate material contextually (a focus on
knowledge creation in the pharmaceutical industry) rather than methodologically or organisationally
(by content).  
Ineligible/irrelevant papers would: 
1. analyse global R&D in other industries. Reasoning: our focus is the pharmaceutical industry
2. analyse aspects not related with global R&D. Reasoning: we aimed at companies that were
affected dramatically by the major changes. For example globalisation would not affect a
company with local R&D operations and local market orientation while the IT revolution
would affect to a much lesser extent a company with a one country R&D orientation.
3. have been published before 1980; Reasoning: most of the major changes happened after
the first biotechnology firms came to be. The IT revolution affected the industry even later,
towards the end of the 1990s. Thus it made sense not to include publications before 1980.
Furthermore a practical consideration has been that publications before 1980 are harder to
locate online. 
4. be written in other languages than English; Reasoning: we argue that the analysed knowledge
domain is dominated by the English language. An additional practical consideration has
been that both researchers shared advanced language fluency only in English.
5. include unpublished material, books, conference papers or other non-reviewed source of
information. Reasoning: such data sources may not be as credible as peer-reviewed journals.
Primary data is extracted from scientific databases available to both reviewers, using specific
search terms based on the above-mentioned inclusion and exclusion criteria developed conjointly.
In order to test the asserted criteria we have devised a pilot search. In the pilot search we have also
included Google Scholar, a freely available commercial search engine that specializes on academic
material. In preparation for the pilot study, we built a classification system that would facilitate our
review (Macpherson & Holt, 2005b). The search string for the pilot is developed in Boolean language
to ensure comparability of results across databases. The choice of the terms in the search string is
derived from the wider knowledge management and pharmaceutical R&D literature. The aim is to
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segregate results on knowledge, pharmaceutical R&D, and globalization. The search string is pre-
sented here: 
Once the pilot was completed, we revised the search string and the classification system. A
detailed summary of the protocol thus developed is presented in Appendix 1.
4. Data Collection and Analysis
We started by performing the pilot study (see Appendix 2), as follows: 
- Individual search in scientific databases, e.g. ProQuest (AB Inform), Elsevier (Science Direct),
Sage, and Wiley Interscience aiming to determine how many relevant articles in total could
be gathered. We examined top-10 results manually. 
- Search on Google Scholar as to assess whether it would be comparable to the scientific
databases. We analysed the top-20 results manually. 
The pilot study revealed important issues. 
First, that the same academic databases differed in each of authors’ respective institutions,
e.g. ABI Proquest encompassed 2,951 publications in one institution and 4,728 in the other. Most
databases proved to have a different portfolio of access in each institution. Differential access made the
conducting of a systematic and consistent literature review a particularly challenging task. Only Science
Direct did not differ in literature scope; thus the search results for both researchers were identical.
Other databases yielded consistent results but proved inadequate for our enterprise. Wiley Interscience
did not yield any results, while Science Direct yielded a very small number of relevant articles and
both were dropped. 
The second issue was that each academic database has had different search facilities leading
to a data gathering process that utilised different search parameters for each database. For example in
ABI one could search text and citations combined while in Science Direct one could not. Concerning
Google Scholar, it gave different results every time we ran the search string, a phenomenon that
did not occur searching in the academic databases. That is attributed to the way Google creates and
presents the results, where even our own search was affecting the order and number of results we
were receiving!
The pilot study revealed two things: Google Scholar provided the most articles and in our
pilot study it had the greatest number of relevant articles. We considered that it had great potential
if used properly, as it brought together papers from a wide range of academic databases and it provided
cached abstract when papers were not available. We concluded that Google Scholar was comparable,
if not superior to academic databases. 
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Pharmaceutical* AND (learn* OR innov*) AND (global* OR international*) AND (research OR R&D)
We added further qualifications and modifications to our search string:
The changes reflected partially the idiosyncratic nature of the Google Scholar search engine.
The Google scholar tool automatically assumes an “AND” between words. The addition of the
“ISSN” qualification assisted in focusing on published material. Furthermore, we restricted our
search to “Business, Administration, Finance, and Economics” and “Social Sciences, Arts, and
Humanities”. 
We used the refined search string in Google Scholar. Results were then input into Endnote.
Our investigation looked at papers from the last 20 years and identified 672 papers potentially relevant
to our search. These were then viewed manually. A total of 253 were removed (146 were institutional
reports, working papers or other material that did not qualify as journal articles, 55 were books, and 52
were duplicate records). The remaining 419 articles were cross-examined for records in other databases.
The results are portrayed in Figure 1.
It was quite clear that Google scholar integrated results from all three academic databases.
Ingenta and Taylor and Francis are explicitly and fully incorporated in the Google Scholar with
links after every record leading directly to the appropriate entry in the database. Google contained
more records than those that could be found in each academic database in isolation. However since
ABI is not included in the Google scholar we could not conclusively say that Google contains all
the possible records from ABI. The records from our population were identified manually. Only 40
262
Saur-Amaral & Kofinas
Pharmaceutical innovation (knowledge OR learning OR learn) (global OR international) (research OR R&D) ISSN
Figure 1. Relationship of inclusion among records identified in Google Scholar Search with ABI
(Ingenta and Taylor & Francis)
ABI
(159)
Ingenta
(276)
Taylor
(194)
4893
157
records (about 10% of the total) were present in all three academic databases indicating that Google
Scholar casts a much wider net of search than any of the other academic databases. 
For an accurate classification of our data, we use two software tools: Endnote and NVivo. Endnote
is more efficient in performing simple content analysis and assisted us originally with the categori-
zation of the articles. The qualitative software NVivo is a useful tool for performing qualitative research
(Hold, 2004; Richards, 2004) and is used here to analyse the abstracts of the most relevant articles,
aiming to identify patterns. Thus we could identify potentially important trends and present their
implications on current research and policy making, pointing out recommendations and insights on R&D
practices and R&D management in pharmaceutical industry, a procedure consistent with similar
systematic reviews in the management literature (Macpherson & Holt, 2005a; Thorpe et al., 2005).
Once the sample was put in Endnote, we refined the classification system by adding two classi-
fication dimensions. The first separated articles into relevant, peripheral and irrelevant as determined
by the presence or absence of our five core concepts. The second distinguished between theoretical
and empirical material. This classification system further reduced the sample size of the articles
and allowed for more detailed examination of our findings. However, a content search performed
in Endnote revealed that it is rather difficult to identify articles that would be primary according to
our original classification scheme, which was based only on abstract and title content analysis. 
It became quickly apparent that the original Google search examined the whole article rather
than just the title/abstract combination. This led to a relaxation of our original requirement for primary
(presence of all five core concepts in the article). Four concepts would suffice to label an article as
primary while 3 terms would label it peripheral. Based on this reviewed classification scheme, we
categorized the 419 papers in Endnote, based on individual abstract analysis performed by the two
reviewers conjointly (to ensure validity). We obtained 45 relevant records for our qualitative analysis.
These articles (see Appendix 3) were isolated in another Endnote library and their titles and abstracts
were exported to an NVivo project. A roadmap of the review scope and protocol can be seen in Figure 2.
The NVivo approach was two-pronged. 
First a grounded-theory approach was used to identify the key concepts. One reviewer per-
formed free coding on all 45 abstracts and built a hierarchical tree of respective codes. Similar codes
were merged and a final model was built in order to most objectively describe the nature and quality of
the information contained in the abstracts examined. Via an iterative process the final hierarchical
model was synthesized. This model is presented in Appendix 4, whilst statistical data on which themes
appeared more frequently in the analyzed records are illustrated in Appendix 5. 
As it can be observed from the model, the considered abstracts indicate extensive links between
the pharmaceutical industry and, mainly, biotechnology, with a few links to the paper, food and
forestry (!) industry (can be considered an outlier). 58% of all records pointed to linkages to other
industries (predominantly Biotechnology). This is an indication of the pharmaceutical industry’s
efforts to complement existing knowledge by creating synergies with this emerging industry. This
result is hardly surprising.  
34% of all records considered the pharmaceutical industry’s context. Issues like the new scope
of health, the role of customers are mentioned and the emphasis given to regulatory issues (85% of
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all records relating to context) reflects an important concern of its relevance/impact to the business
and its innovation patterns. We also note a specific interest given to patenting (free circulation of
knowledge and uniform rules versus tighter enforcement of patents). This also came as no surprise,
since we analyzed knowledge processes in a knowledge-intensive and global industry, where regu-
lations and patenting play an important role in securing knowledge creation and determining
knowledge distribution and exploitation.
Under the globalization heading, issues like distributed production, distributed innovation,
new organizational forms and increasing competitiveness (e.g. networks, strategic alliances, mergers,
clustering) as well as technological interdependence are at the core of analyzed material. However,
more interest was shown to distributed innovation and the subsequent exploitation of innovation
resources all over the world to enhance the efficiency of the drug development process. New organi-
zational forms were also at the core of academic discourse, with particular emphasis given to the
importance of localization (89% of all records in the Globalization category). This is also to be expected
in a global context.
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Figure 2. Roadmap of the Systematic Literature Review
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In addition, pharmaceutical industry appeared to look into rigorous HR management practices,
giving emphasis to knowledge workers’ autonomy, to knowledge sharing between them and to the
creation of a global mindset among these workers (e.g. mobility, knowledge combination). 24% of the
records gave importance to HR management and the role of knowledge workers, covering issues
linked to their desirable autonomy to exploit duly their competences.
Second, and in order to validate the original coding, the other reviewer utilised the developed
framework and applied it to re-code the abstracts and titles of the 45 articles. The re-coding was done
independently (the second coder had no knowledge of results of the first coding). The desired outcome
was to test the robustness and external validity of the framework previously developed. It also gave
space to revise the internal validity and reach an agreement over both construct and concept validity of
the hierarchical tree. 
Results proved quite positive. The hierarchical tree was revised yet not substantially. There
was some reshuffling and some new codes developed (see Appendix 6). There was an estimated
15% difference between the node structure of the hierarchical tree of the first reviewer and the second.
This indicated that the result was a robust construct with a relatively high degree of internal validity.
There were differences in the percentages coded under each node (see Appendices 5 and 7). Mostly
the second coding pushed up the percentages of three of the four main nodes (context/industries/
globalisation) by 20-5%, which indicated that second coding considered broader understandings of
the concepts than the first one. That may be a direct result of the fact that the second tree had fewer
nodes due to additional reiterations by the authors. The only notable exception was in the fourth, the HRM
parent node where the second author actually seemed to have taken a more limited understanding
of the node than the first author. 
Another interesting issue was that in this second phase, context became more important (63% of
all records). Same happened to knowledge production, research intensive networks, importance of funding,
localization in clusters, networks and internationalization of technology. However, the main conclusions
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Figure 3. Records’ Distribution on Publication Year (all 45 considered for qualitative analysis)
remained intact, which reinforces the validity of the model and its capacity to describe accurately the
analyzed records.  
Alongside the coding, statistical data was gathered as to the publication year of each paper and
their empirical or theoretical base wherever it was possible to identify. Interestingly, papers’ distribution
by publication year (as Figure 2 portrays) reflects how the field of knowledge creation in the pharma-
ceutical R&D context has only recently been addressed by the academic community.
The filtered records of our analysis were published between 1999 and 2005. We recall that our
search covered papers with publication date from 1980. This may signify one of two things: either issues
related to globalization of innovation and knowledge production processes in the pharmaceutical
industry fell into academic attention only after 1996-7, or that databases used by Google Scholar only
made available papers published in the last 7-8 years. The first explanation is more plausible since
Ingenta and other databases, which are already included in the Google Scholar, contain data much
before 1996.
As of the empirical – theoretical distribution, the classification work was performed conjointly by
the two researchers. 49% of the papers were theoretical and 47% were of empirical nature, which
indicates an equilibrated distribution. If we go back to the roots of systematic reviews, we note that
usually only empirical works were considered for this kind of studies. Yet, theoretical papers can
provide particularly good insights and should be, in our opinion, considered for the purpose of a
systematic review.
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Figure 4. Records’ Distribution on type of paper (all 45 considered for qualitative analysis)
5. Findings 
Summarizing, key identified trends that affected knowledge creation processes in pharmaceutical
industry during the analyzed period were the following:
- Strong linkages with the biotechnology industry; 
- High influence of and importance given to regulatory environment, with contradictory ten-
dencies on knowledge freedom and protection;
- Strong emphasis on the globalization issue, with focus on distributed innovation (especially
linked with knowledge production), new organizational forms to better deal with it (emphasis
given to funding, clusters and networks) and technology (especially internationalization of
technology);
- Emerging issues like the new scope of health and competences (knowledge workers’ autonomy
and global mindset).
Looking at these trends, a first insight is that new knowledge creation in pharmaceuticals and
its linkage to aspects of localization, regional funding, global regulations needs yet to be properly
addressed; further study is required to identify appropriate (and more flexible) methods and instruments
to perform the knowledge creation processes efficiently. A conspicuous absence in our findings is that
of the information technology (IT) as a factor. Very few articles refer to its importance in knowledge
management, even though it is frequently mentioned in generic knowledge management literature
(e.g. Cabrera & Cabrera, 2002; Gray, 2001; Lerer & Piper, 2003; Nonaka, Reinmoller, & Toyama, 2001).
This could indicate either that pharmaceutical industry has not made much progress on IT-based
KM or that the search should have focused on IT usage in fields related to the pharmaceutical industry
such as bioinformatics or that the advances in IT are secretive and there is little public information.
In addition one should note that certain technologies such as genomics, proteomics and even the field
of biotechnology are implicitly yet certainly based on IT (Galambos & Sturchio, 1998; Howells, 2002;
McMeekin & Harvey, 2002).
Localization issues focus on clustering and networks. It is unclear from our data whether this is
evidence of the emergence of a network society or the natural evolution of simpler approaches based
on regional/local agglomeration of specialized knowledge i.e. universities or specific research organi-
zations. Future research should consider whether clustering is an appropriate way to look at locali-
zation issues, whereas other simpler explanations could be considered. The bewildering variety of
cluster/network arrangements found in the review may indicate that scholars either are unclear of
the investigated phenomena, or that their rhetoric in pharmaceutical R&D literature has advanced way
beyond the actual developments in the industry. However, armed with the information obtained on
publication dates one would probably side with the former version, i.e. lack of clarity. Pharmaceutical
industry is a relatively slow industry and the ideas of clustering, networks and national innovation
systems were developed in the early 1990’s. Thus the relative dearth of articles before 1996 may
indicate that pharmaceutical firms or the academics have not caught up with changes brought about by
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these new organisational arrangements (networking and clusters), new IT and technology developments
(biotechnology, genomics, proteomics), and changes in regulation regime. 
In what concerns the role of knowledge creation in global pharmaceutical R&D it is addressed
only indirectly in the analyzed records, in terms of innovation and general regulations. Knowledge
creation seems to underlie all strategic decisions of global pharmaceutical R&D but as a process is never
put explicitly in focus. However the role of knowledge processes is discussed, especially when it
comes to distributed innovation and HR management. Thus more studies that focus explicitly on
the role of knowledge creation in pharmaceuticals or on the systematic management of knowledge
processes may help revealing efficient management practices both for research and general strategy in
the pharmaceutical industry.
6. Policy implications
The identified trends may serve as inspiration to policy-makers, as follows. 
Institutional mechanisms and incentives may be further developed at international levels in
order to enhance cooperation with the biotechnology partners and to complement the current tendency
of limited collaboration initiatives with commercial ends. This is important so as to stimulate coope-
ration between pharmaceutical firms and biotechnology ones, especially in the discovery phase, and
thus to facilitate a common language between these partners. It may increase competitiveness on both
sides and benefit patients, while increasing the available knowledge base for timely embodiment in
new products and services.
Policy makers should include a global mindset, a global reasoning in their approaches. If pharma-
ceutical industry and the knowledge creation processes for new drug development are global, albeit
concentrated in Triad countries (only lately more open to other developing countries, too), what reason
is it to make nationally bounded policies for such an industry? We believe policy makers could be
true knowledge workers with global perspectives and collaborate with the pharmaceutical industry,
biotech partners, regulatory authorities, decision makers (physicians, pharmaceutical profession,
patients) so as to benefit all actors of an increasingly global society. 
Regulatory entities should continue working at an international level to achieve consensus and
harmonize regulations, in order to relieve pharmaceutical firms from increasing and unnecessary paper
work and time losses. ICH (International Conference for Harmonization) in its effort to define good
practices for R&D and production is one step in the right direction; it needs though to be further
developed. EMEA’s work on European pharmaceutical market is another good step, by approving
medicines for usage in any European market; however pricing is still established nationally and process
is difficult and longer than it should be. A desirable development would be setting up market entry
process valid for several key countries, with pricing and remaining details processed batch-like with
common requirements. By reducing time-to-market and harmonizing regulations there is more time
and money for knowledge creation and commercialization.
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And maybe if all the funds spent on bureaucracy would be spent on ethical, less profitable
research on cures for orphan diseases (e.g. malaria, or other developing countries’ devastating plagues)
there may be a way to address the paradox between freedom of knowledge and the corresponding
need for protecting it. 
7. Conclusions
Pharmaceutical innovation is paramount now more than ever as the environment constraints
increase and the market becomes more competitive. New knowledge creation is the key way to
expand the markets ahead of the increasing global constraints and various market pressures. So
while the pharmaceutical industry expands its networks and enhances its HR practices, it has to
pay attention to how the new arrangements enhance its knowledge creation processes or dilute the
existing capacities to create new knowledge. The global element becomes more and more prominent
and the companies have to consider it in their calculations for further expansion and growth.
Knowledge work implies a certain degree of freedom. Human resources from this industry are
increasingly considered knowledge workers, and are given considerable autonomy to create and utilize
knowledge in order to respond to existing challenges and prepare for new ones. Pharmaceutical R&D
managers are viewed as knowledge managers and their behaviour and management practices have
to adjust accordingly so as to inspire their subordinates and colleagues to think globally and creatively.
This empowerment and flexibility is reflected in the rise of the new organisational forms and networks
prominent in the results of this study. Thus, as the R&D function mutates and changes to meet this
new and daring knowledge world, possible structural arrangements diversify accordingly to meet
the challenge. Yet the pharmaceutical industry has witnessed increasing regulation and the organi-
sational knowledge processes seem intimately related to knowledge protection patterns and institutional
regulations. The heavy regulatory environment would be expected as health is a sensitive issue. There
are concerns about biotechnology, about the harmonisation of regulations for the benefit of the public,
there is talk about the new scope of health and pressure to reduce prices and increase safety. However
it highlights a potential friction between the freedom implied in new knowledge production and the
pressure for regulation, a dialectic that is transparent and prominent in our research. This may have
detrimental effect to the capacity of the industry to innovate in the long term, and a new balance between
regulation and creativity should be seriously considered by policy makers, especially in the Triad countries.
With a two century experience in research and a historical resilience to various socio-economic
and technological upheavals, the pharmaceutical industry has repeatedly proven its flexibility and
adaptability to new challenges. Probably the key conclusion of this research, tentative though it
may be, is that we lay in the middle of dramatic changes regarding the way knowledge creation is
pursued by contemporary pharmaceutical R&D processes, yet their effects in the pharmaceutical
knowledge base are still fuzzy. It may take several years before we have a clearer picture of what
structures of global pharmaceutical R&D will prevail in the industry’s constant efforts for knowledge
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creation and innovation. Thus a need to ascertain the new paradigm will require another thorough
systematic review that may clarify the fuzzy elements that we identified.
We end with a short note on the methods used in this article. The rigorous classification and
analysis of the results from the Google scholar database search has provided us with an initial sample
of almost 700 papers pertaining to pharmaceutical innovation and knowledge creation in a global
setting. We then considered a bit more than 400 papers for our initial classification and around
10% of that were retained for qualitative analysis. Even by using strict criteria to perform searches,
technical limitations of the database search platform may require a human double-check of results.
In the case of Google Scholar, as it only performs search on full text and does not allow search
refinements to abstract and title, the number of final relevant records was quickly diminished. This
then casts some doubt to the original assessment that the Google Scholar may be superior to the
academic databases. Even though it evidently provides far more hits per category and is much broader
in scope than academic databases, its limited search engine does not allow sophisticated searching
and thus renders the breadth advantage meaningless.
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Resumo. A indústria farmacêutica baseia-se na utilização intensiva de conhecimento e na investigação
e desenvolvimento de novos medicamentos. Devido às mudanças tecnológicas, sociopolíticas e organi-
zacionais, a base de conhecimento utilizada para conquistar e manter as vantagens competitivas tem estado
a evoluir constantemente. Existe uma lacuna na análise das relações e dos efeitos daquelas mudanças
nos processos de criação de conhecimento associados às actividades farmacêuticas de I&D. O nosso
artigo procura colmatar esta mesma lacuna. Recorremos a uma abordagem original de investigação – a
revisão sistemática da literatura – e procurámos identificar as tendências que afectam actualmente a
criação de conhecimento nas actividades de I&D internacional/global. Considerámos na revisão artigos
científicos publicados entre 1980 e 2005. Os principais resultados incluem as tendências promissoras na
inovação farmacêutica e na gestão de recursos humanos, e as suas potenciais implicações nas práticas
actuais de I&D na indústria farmacêutica, considerando as perspectivas da gestão e da governação. 
Palavras-chave: Criação de conhecimento, indústria farmacêutica, revisão sistemática da literatura,
I&D global.
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APPENDIX 1
—  Summary of the protocol  —
Steps Criteria Checks
Study identification (inclusion or Global R&D in pharmaceutical and Cross-read the paper/abstract to ensure
exclusion) knowledge processes, focus on that the search equation is respected.
knowledge creation. This is important as database search
may fail.
Assessment of quality Scientific publications, and reviewers’ ISSN, citation statistics (if available),
conjoint evaluation (in case of doubt, number of links in Google (if available).
with justification and record of the
rationale).
Data collection and extraction Trends affecting knowledge creation in Ensure the comprehension of the
global pharmaceutical industry. Usage knowledge creation concept is the same
of Endnote software for storage and as reviewers’ understanding.
subsequent analysis.
Data analysis NVivo software/grounded theory Double coding to ensure validity.
approach to codification.
APPENDIX 2
—  Results of the pilot study  —
GENERIC RESULTS
Number of results
Search string Scope Date of search Date range Sage Wiley ABI Science Direct Google
Pharmaceutical* Title and 10 Jan 2005 1980-2005 312 0 128 53 208
AND (learn* OR abstract
know*) AND innov*
AND (global* OR Title and 10 Jan 2005 1980-2005 273 0 39 52 183
international) abstract
AND (research OR Title and 10 Jan 2005 1980-2005 270 0 25 50 182
R&D)
SAGE (EXAUSTIVE SEARCH)
Selected results Primary Secondary Peripheral Conceptual Irrelevant Comments
10 0 1 2 0 6 1 record difficult to evaluate.
ABI (EXHAUSTIVE SEARCH)
Selected results Primary Secondary Peripheral Conceptual Irrelevant Comments
10 6 3 1 0 0 Good results, apparently relevant.
However, small initial sample (25
results only).
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SCIENCE DIRECT (EXAUSTIVE SEARCH)
Selected results Primary Secondary Peripheral Conceptual Irrelevant Comments
10 2 0 0 0 8 Mainly irrelevant results.
GOOGLE (EXHAUSTIVE SEARCH)
Selected results Primary Secondary Peripheral Conceptual Irrelevant Comments
21 1 0 6 0 10 A single relevant record. Six
peripherals. High initial sample (182).
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APPENDIX 4
—  NVivo model after grounded theory approach  —
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APPENDIX 5
—  Statistical data on NVivo model (grounded theory approach)  —
Theme Number of records % of parent % of all
Pharmaceutical industry 38 100% 100%
Other industries 32 58% 58%
Biotechnology 29 86% 50%
Paper industry 1 5% 3%
Context 13 34% 34%
New scope of health 1 8% 3%
Customers 1 8% 3%
Regulations 11 85% 29%
Patenting 5 45% 13%
Uniform rules 3 60% 8%
Enforcement of patents 1 20% 3%
Free circulation of knowledge 1 20% 3%
Guidance 2 18% 5%
Use of technology 2 100% 5%
For knowledge creation 1 9% 3%
Institutional models 1 100% 3%
Various industrial specializations 1 100% 3%
For technology acceptance 1 9% 3%
For networks and consortia 2 18% 5%
Globalization 19 50% 50%
Distributed production 2 11% 5%
Distributed innovation 11 58% 29%
High value-added areas 5 45% 13%
Drug development process 4 80% 11%
Knowledge production 3 27% 8%
Knowledge usage 2 18% 5%
Wide applicability of production 1 9% 3%
New organizational forms 9 47% 24%
ICT 3 33% 8%
Outside clusters collaborations 1 33% 3%
Research intensive networks 1 11% 3%
Established knowledge clusters 1 11% 3%
Importance of localization 8 89% 21%
In clusters 6 75% 16%
Outside clusters 2 25% 5%
Networks 2 22% 5%
Research collaborations 1 11% 3%
Collaborative alliances 1 11% 3%
Technology 3 16% 8%
Importance of learning 1 33% 3%
Internationalization of technology 1 33% 3%
HR management 9 24% 24%
Knowledge workers 4 44% 11%
Knowledge sharing 1 11% 3%
Recruitment and mobility 2 22% 5%
Global pharmaceutical industry 1 11% 3%
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APPENDIX 6
—  NVivo model after second (independent) review  —
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APPENDIX 7
—  Statistical data on NVivo model (after second review)  —
Theme Number of records % of parent % of all
Pharmaceutical industry 38 100% 100%
Other industries 26 68% 68%
Biotechnology 24 92% 63%
Others 5 19% 13%
Context 24 63% 63%
New scope of health 3 13% 8%
Customers 1 4% 3%
Regulations – Institutions 23 96% 61%
Uniform rules and regulations 3 13% 8%
Patents and circulation of knowledge 3 13% 8%
Ethical guidance on technological use 9 38% 24%
Knowledge creation – Institutional models 2 8% 5%
Knowledge creation – Various industrial specializations 4 17% 11%
For technology acceptance 2 8% 5%
For networks and consortia 7 30% 18%
Markets 4 17% 11%
Globalization 29 76% 76%
Distributed production 3 10% 8%
Distributed innovation 16 55% 42%
Drug development process 4 25% 11%
Knowledge production    10 63% 26%
Knowledge usage 2 13% 5%
Wide applicability of production 1 6% 3%
New organizational forms 18 62% 47%
ICT 1 6% 3%
Research intensive networks 4 22% 11%
Importance of funding 5 28% 13%
Localization in clusters 7 39% 18%
Localization outside clusters 2 11% 5%
Networks 6 33% 16%
Clusters 6 33% 16%
Research collaborations 1 6% 3%
Collaborative alliances 2 11% 5%
Technology 9 31% 24%
Importance of learning 2 22% 5%
Internationalization of technology 1 11% 3%
Internationalization of technology 5 56% 13%
HR management 7 18% 18%
Knowledge workers 4 57% 11%
Knowledge sharing 2 29% 5%
Recruitment and mobility 2 29% 5%
Global pharmaceutical industry 3 43% 8%
